Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6158143 | American Journal of Kidney Diseases | 2012 | 9 Pages |
Abstract
Because transplant with an HCV+ kidney may reduce waiting-time by more than a year for an HCV+ patient and there is a high risk of kidney waitlist mortality, a 2% increased rate of adverse liver outcomes and 2% increased rate of death at 3 years should not universally preclude the use of HCV+ kidneys when the intended recipient is also HCV+.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Lauren M. ScM, Thomas G. MD, Dorry L. MD, PhD,